iBio
IBIO
91 hedge funds and large institutions have $68.4M invested in iBio in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 15 reducing their positions, and 14 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 15
114% more capital invested
Capital invested by funds: $31.9M → $68.4M (+$36.5M)
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 89 → 91 (+2)
0.01% more ownership
Funds ownership: 0.03% → 0.04% (+0.01%)
30% less call options, than puts
Call options by funds: $1.8M | Put options by funds: $2.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12M |
| 2 |
BlackRock
New York
|
+$6.72M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.53M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.43M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$743K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$402K |
| 2 |
Morgan Stanley
New York
|
-$354K |
| 3 |
HCM
Harvey Capital Management
Palm Beach,
Florida
|
-$78K |
| 4 |
QC
QCM Cayman
Houston,
Texas
|
-$74.1K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$63.6K |
IBIO Hedge Fund Activity: Q1 2021 in Review
91 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q1 2021, worth a combined $68.4M — up 114% from $31.9M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new IBIO positions and 14 closed out — a net gain of 3 holders — while 40 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $12M. The largest seller was Wells Fargo, cutting an estimated $402K.
- 91 institutional investors held iBio (IBIO) as of Q1 2021, up from 89 in Q4 2020.
- Funds reported $68.4M of iBio stock for Q1 2021, up 114% quarter-over-quarter.
- 17 funds opened new iBio positions in Q1 2021 and 14 closed out, a net change of +3 holders.
- The largest iBio buyer in Q1 2021 was Vanguard Group, an estimated $12M added.
- The largest iBio seller in Q1 2021 was Wells Fargo, an estimated $402K sold.
Based on aggregated 13F filings for Q1 2021.